摘要
目的 探讨贝伐珠单抗联合紫杉醇对转移性乳腺癌患者免疫功能的影响。方法 选取2018年1月至2022年4月南昌市第三医院收治的100例转移性乳腺癌患者作为研究对象,按随机数字表法分为对照组与观察组,各50例。对照组接受紫杉醇治疗,观察组接受贝伐珠单抗联合紫杉醇治疗。于治疗4个周期后评估疗效,比较两组治疗前后血清肿瘤标志物、免疫功能指标,记录不良反应。结果 观察组疾病控制率(DCR)为66.00%,高于对照组的46.00%(P<0.05)。治疗后观察组癌胚抗原(CEA)、糖类抗原125(CA125)、细胞角蛋白19片段(CYFRA21-1)水平低于对照组,差异有统计学意义(P<0.05)。治疗后观察组CD3^(+)、CD4^(+)高于对照组,CD8^(+)、骨髓源性抑制细胞(MDSCs)、调节性T细胞(Tregs)低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率(20.00%vs.16.00%)比较,差异无统计学意义(P>0.05)。结论 贝伐珠单抗联合紫杉醇治疗转移性乳腺癌疗效确切,可降低肿瘤标志物的表达,提高免疫功能,且未增加不良反应。
Objective To explore the effect of bevacizumab combined with paclitaxel on immune function in patients with metastatic breast cancer.Methods A total of 100 patients with metastatic breast cancer admitted to Nanchang Third Hospital from January 2018 to April 2022 were selected as the study objects,and were divided into control group and observation group according to random number table method,with 50 cases in each group.The control group received paclitaxel treatment,and the observation group received bevacizumab combined with paclitaxel.The therapeutic effect was evaluated after 4 cycles of treatment.Serum tumor markers and immune function indexes were compared between the two groups before and after treatment,and adverse reactions were recorded.Results The disease control rate(DCR)in observation group was 66.00%,which was higher than that in control group(46.00%)(P<0.05).After treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and cytokeratin 19 fragment(CYFRA21-1)in observation group were lower than those in control group,and the differences were statistically significant(P<0.05).After treatment,CD3^(+)and CD4^(+)in observation group were higher than those in control group,and CD8^(+),bone marrow-derived suppressor cells(MDSCs)and regulatory T cells(Tregs)were lower than those in control group,with statistical significance(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(20.00%vs.16.00%)(P>0.05).Conclusion The combination of bevacizumab and paclitaxel is effective in the treatment of metastatic breast cancer,which can reduce the expression of tumor markers,improve immune function,and does not increase adverse reactions.
作者
周新华
熊迎
邱平
付晶晶
ZHOU Xin-Hua;XIONG Ying;QIU Ping;FU Jing-Jing(Department of Clinical Laboratory,Nanchang Third Hospital,Nanchang 330025,China;Department of Orthopedics,Nanchang Third Hospital,Nanchang 330025,China)
出处
《中国药物经济学》
2023年第12期87-90,95,共5页
China Journal of Pharmaceutical Economics
基金
江西省卫生健康委科技计划项目(202311264)。
